Guidance, NICE advice and quality standards in development | Guidance

Showing 291 to 300 of 401

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]	Technology appraisal guidance	TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]	Technology appraisal guidance	TBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]	Technology appraisal guidance	28 January 2026
Polycystic ovary syndrome: assessment and management	NICE guideline	3 November 2026
Prostate cancer: diagnosis and management (update)	NICE guideline	TBC
Psoriasis: assessment and management (CG153)	NICE guideline	TBC
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure	Diagnostics guidance	20 January 2026
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]	Technology appraisal guidance	7 April 2027
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]	Technology appraisal guidance	TBC